94 related articles for article (PubMed ID: 25855135)
1. Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer.
Wiśniewski A; Kowal A; Wyrodek E; Nowak I; Majorczyk E; Wagner M; Pawlak-Adamska E; Jankowska R; Ślesak B; Frydecka I; Kuśnierczyk P
Tissue Antigens; 2015 Jun; 85(6):466-75. PubMed ID: 25855135
[TBL] [Abstract][Full Text] [Related]
2. MiRNA-mediated control of HLA-G expression and function.
Manaster I; Goldman-Wohl D; Greenfield C; Nachmani D; Tsukerman P; Hamani Y; Yagel S; Mandelboim O
PLoS One; 2012; 7(3):e33395. PubMed ID: 22438923
[TBL] [Abstract][Full Text] [Related]
3. Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis.
de Almeida BS; Muniz YCN; Prompt AH; Castelli EC; Mendes-Junior CT; Donadi EA
Hum Immunol; 2018 Oct; 79(10):724-735. PubMed ID: 30102938
[TBL] [Abstract][Full Text] [Related]
4. The structure of the atypical killer cell immunoglobulin-like receptor, KIR2DL4.
Moradi S; Berry R; Pymm P; Hitchen C; Beckham SA; Wilce MC; Walpole NG; Clements CS; Reid HH; Perugini MA; Brooks AG; Rossjohn J; Vivian JP
J Biol Chem; 2015 Apr; 290(16):10460-71. PubMed ID: 25759384
[TBL] [Abstract][Full Text] [Related]
5. [Research progress on HLA-G in non-small cell lung cancer].
Li R; Guo Z; Zhang X; Xiao L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Feb; 40(2):174-178. PubMed ID: 38284259
[TBL] [Abstract][Full Text] [Related]
6.
Bernit E; Jean E; Marlot B; Laget L; Izard C; Dettori I; Beley S; Gautier I; Agouti I; Frassati C; Pedini P; Picard C; Paganini J; Chiaroni J; Di Cristofaro J
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686397
[TBL] [Abstract][Full Text] [Related]
7. Disulfide bond-mediated dimerization of HLA-G on the cell surface.
Boyson JE; Erskine R; Whitman MC; Chiu M; Lau JM; Koopman LA; Valter MM; Angelisova P; Horejsi V; Strominger JL
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16180-5. PubMed ID: 12454284
[TBL] [Abstract][Full Text] [Related]
8. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
Kudo Y; Haymaker C; Zhang J; Reuben A; Duose DY; Fujimoto J; Roy-Chowdhuri S; Solis Soto LM; Dejima H; Parra ER; Mino B; Abraham R; Ikeda N; Vaporcyan A; Gibbons D; Zhang J; Lang FF; Luthra R; Lee JJ; Moran C; Huse JT; Kadara H; Wistuba II
Ann Oncol; 2019 Sep; 30(9):1521-1530. PubMed ID: 31282941
[TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer.
Kowal A; Wiśniewski A; Kuśnierczyk P; Jankowska R
Thorac Cancer; 2015 Sep; 6(5):613-9. PubMed ID: 26445610
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional and posttranscriptional regulations of the HLA-G gene.
Castelli EC; Veiga-Castelli LC; Yaghi L; Moreau P; Donadi EA
J Immunol Res; 2014; 2014():734068. PubMed ID: 24741620
[TBL] [Abstract][Full Text] [Related]
11. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
McGranahan N; Rosenthal R; Hiley CT; Rowan AJ; Watkins TBK; Wilson GA; Birkbak NJ; Veeriah S; Van Loo P; Herrero J; Swanton C;
Cell; 2017 Nov; 171(6):1259-1271.e11. PubMed ID: 29107330
[TBL] [Abstract][Full Text] [Related]
12. Generation of a blockage monoclonal antibody of LILRB1 against HLA-G.
Shen Y; Zhang R; Jiang X; Yang J
Protein Expr Purif; 2024 Jan; 213():106363. PubMed ID: 37683901
[TBL] [Abstract][Full Text] [Related]
13. HLA-G as a tolerogenic molecule in transplantation and pregnancy.
Rebmann V; da Silva Nardi F; Wagner B; Horn PA
J Immunol Res; 2014; 2014():297073. PubMed ID: 25143957
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of HLA and Susceptibility of Breast Cancer.
Aboulaghras S; Khalid A; Makeen HA; Alhazmi HA; Albratty M; Mohan S; Goh BH; Yeo CI; Tan YS; Bouyahya A
Front Biosci (Landmark Ed); 2024 Feb; 29(2):55. PubMed ID: 38420797
[TBL] [Abstract][Full Text] [Related]
15. HLA-G Neo-Expression on Tumors.
Loustau M; Anna F; Dréan R; Lecomte M; Langlade-Demoyen P; Caumartin J
Front Immunol; 2020; 11():1685. PubMed ID: 32922387
[TBL] [Abstract][Full Text] [Related]
16. The dual role of HLA-G in cancer.
Rouas-Freiss N; Moreau P; LeMaoult J; Carosella ED
J Immunol Res; 2014; 2014():359748. PubMed ID: 24800261
[TBL] [Abstract][Full Text] [Related]
17. Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer.
Merlotti A; Sadacca B; Arribas YA; Ngoma M; Burbage M; Goudot C; Houy A; Rocañín-Arjó A; Lalanne A; Seguin-Givelet A; Lefevre M; Heurtebise-Chrétien S; Baudon B; Oliveira G; Loew D; Carrascal M; Wu CJ; Lantz O; Stern MH; Girard N; Waterfall JJ; Amigorena S
Sci Immunol; 2023 Feb; 8(80):eabm6359. PubMed ID: 36735774
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory properties of HLA-G in infectious diseases.
Amiot L; Vu N; Samson M
J Immunol Res; 2014; 2014():298569. PubMed ID: 24839609
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.
Zienolddiny S; Skaug V
Lung Cancer (Auckl); 2012; 3():1-14. PubMed ID: 28210120
[TBL] [Abstract][Full Text] [Related]
20. Human leukocyte antigen G and renal allograft transplant.
Farid E; Al-Wedaie F; Tabbara K; El-Agroudy AE; Al-Ghareeb SM
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():371-6. PubMed ID: 25894193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
